Navigation Links
Chiltern Announces Additional Investment in Endpoint
Date:6/16/2011

LONDON, June 16, 2011 /PRNewswire/ -- Chiltern International Limited (Chiltern), a global contract research organization (CRO) announced an additional financial investment in Endpoint Clinical, Inc. (endpoint) further strengthening their strategic partnership with the company established in April 2009.

Glenn Kerkhof, Chiltern CEO, stated, "Chiltern's decision to increase our investment in endpoint reflects our aligned vision for the future of endpoint's PULSE platform, enabling endpoint to provide an unparalleled combination of premium client service and advanced technology solutions. Jon Dole and Tom O'Connell of endpoint have brought a new level of energy and innovation to Interactive Response Technology (IRT). Since our partnership began over a year ago, endpoint has delivered high quality, cost effective services to clients with both accuracy and speed. endpoint is successfully responding with best- in-class IVR/IWR solutions and as a result exceeding client expectations."

Jonathan Dole, endpoint CEO, stated, "Chiltern has been an excellent partner for us over the past year, and we couldn't be more pleased with their continued support in our vision for IRT. Chiltern's global footprint and their overall support of our growing business have proven invaluable in moving us forward. Chiltern's enthusiasm and investment affirms our confidence in the solutions we are bringing to the marketplace. With PULSE we are delighting our clients with our fresh and logical approach to systems development, giving our customers the agility they need in a constantly changing R&D environment."

PULSE is endpoint's fully configurable system which allows users to design and deploy clinical trial IRT systems at a fraction of the time and cost of other providers, was launched in January 2010. Providing both high speed of deployment and flawless quality, PULSE simultaneously designs systems that can be ac
'/>"/>

SOURCE Chiltern
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Chiltern Early Phase: Fully Integrated and Business Ready
2. Chiltern Is a Nominee on the SCRIP CRO of the Year Award Shortlist
3. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
4. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
5. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
6. Anesiva Announces Second Quarter 2008 Financial Results and Update
7. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
8. Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008
9. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
10. China Yingxia International, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
11. ThirdBiotech Announces Kemeta as Newest Sponsor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... 04, 2015 PRC Clinical, ... San Francisco Bay Area, will exhibit and present at ... 2015 on March 25th and 26th in Tel ... relationships with Israeli life science companies seeking to conduct ... company’s services span all phases of human trials, from ...
(Date:3/4/2015)... March 4, 2015  BioClinica®, Inc., a ... provider, today announced that clinical trial professionals ... at its annual European User Conference in ... discuss the use of its eClinical technologies ... technologies include: the Microsoft Office-Smart OnPoint CTMS; ...
(Date:3/4/2015)... Launched by the Assistance Publique - ... 2011, ,SARAH, - the French national collaborative randomized ... advanced hepatocellular carcinoma (HCC) has enrolled more than 400 ... a large French study of patients with advanced, inoperable ... patient enrolment, exceeding its 400-patient target, according to its ...
(Date:3/3/2015)... /PRNewswire/ - Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), ... that target the underlying mechanisms of cancer, today reported ... December 31, 2014. Effective July 17, 2014, ... 31 to December 31. As a result of that ... the quarter and the seven months ended December 31, ...
Breaking Biology Technology:PRC Clinical to Present at Inaugural Outsourcing in Clinical Trials Israel Conference 2015 on March 25 and 26th in Tel Aviv 2PRC Clinical to Present at Inaugural Outsourcing in Clinical Trials Israel Conference 2015 on March 25 and 26th in Tel Aviv 3PRC Clinical to Present at Inaugural Outsourcing in Clinical Trials Israel Conference 2015 on March 25 and 26th in Tel Aviv 4BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 2BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 3Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 2Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 3Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 4Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 5Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 2Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 3Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 4Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 5Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 6Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 7Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 8Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 9Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 10Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 11Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 12
... BETHESDA, Md., Oct. 24, 2011 Spherix Incorporated ... in biotechnology for therapy in diabetes, metabolic syndrome ... consulting services to food, supplement, biotechnology and pharmaceutical ... of D-tagatose and SPX-106) reduced dyslipidemia in new ...
... DLVR Therapeutics Inc. ("DLVR") - a privately-held ... based on its proprietary high density lipoprotein-like nanoparticle ... seed round investment bringing the total raised to ... Innovation joins the University Health Network (UHN) and ...
... 24, 2011 Marshall Edwards, Inc. (Nasdaq: MSHL ... novel therapeutics targeting cancer metabolism, announced today that Charles Baltic, ... has been appointed to its board of directors. The appointment ... six and the number of independent directors to five. ...
Cached Biology Technology:Spherix Announces Results from New Preclinical Studies Showing SPX-106T Produces Significant Reductions in Cholesterol, Fat Deposition and Body Weight 2Spherix Announces Results from New Preclinical Studies Showing SPX-106T Produces Significant Reductions in Cholesterol, Fat Deposition and Body Weight 3Spherix Announces Results from New Preclinical Studies Showing SPX-106T Produces Significant Reductions in Cholesterol, Fat Deposition and Body Weight 4DLVR Therapeutics Inc. Raises Additional Capital Adding MaRS Innovation to Investor Base 2DLVR Therapeutics Inc. Raises Additional Capital Adding MaRS Innovation to Investor Base 3Marshall Edwards Appoints Healthcare Investment Banking Veteran Charles Baltic to Board of Directors 2Marshall Edwards Appoints Healthcare Investment Banking Veteran Charles Baltic to Board of Directors 3
(Date:2/5/2015)... 2015  Marken is starting its 35 th ... a new marketing campaign to solidify its place as ... campaign focuses on First as a primary ... The first headline in the series, ... its client,s priorities. Marken recognizes the need to protect ...
(Date:2/5/2015)... Jan. 28, 2015 NXT-ID, Inc. (NASDAQ: ... a biometric authentication company focused on the growing mobile ... RedChip Global Online CEO Conference on January 29 th ... Gino Pereira , CEO of NXT-ID will present and ... the Wocket smart wallet and its full suite of ...
(Date:1/22/2015)... 2015 Valid S.A. ("Company") (BM&FBOVESPA: VLID3 ON), is pleased ... State of Washington,s Department of Licensing, ... and central issuance system for driver,s licenses and identification cards ... planning and development will start in January 2015, with enrollment ...
Breaking Biology News(10 mins):Marken Launches New Patient-Centric Campaign 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3Valid USA Signs Contract For Washington Driver's License Issuance 2
... use knowledge about methane production by cold-weather microbes on ... similar, carbon-based microbes that could have evolved on Mars, ... three-year project, funded by a $2.4 million grant from ... program, will be led by biogeochemist Lisa Pratt. Her ...
... for informatics professionals, has weighed in on the Federal ... Office of the National Coordinator,s (ONC) call for comments ... set forth by the U.S. Congress and the Administration. ... MD, summarizes AMIA,s comments simply: "Because health IT ...
... 11 May 2011 - Two new research studies published ... in brain development that emerge as vulnerable individuals develop ... with a deletion of a small section of chromosome ... of abnormalities in the structure of the heart and ...
Cached Biology News:NASA project eyes climate change in Greenland -- with a third eye on Mars 2NASA project eyes climate change in Greenland -- with a third eye on Mars 3AMIA identifies areas to strengthen Federal health IT strategic plan 2Brain development goes off track as vulnerable individuals develop schizophrenia 2
... quadrupole 1200L sets the new standard ... - incorporating the latest technologies and ... chromatography analytical needs. The Atmospheric ... Transmission Quadrupole Analyzer provide superior selectivity ...
Human beta IG-H3 MAb (Clone 348506) Keywords: BIGH3, betaIG-H3 Protein Family: Extracellular Matrix Molecules...
Catalase (Control)...
Human RELT/TNFRSF19L Affinity Purified Polyclonal Ab...
Biology Products: